1. Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen 
H. Joachim Deeg, Barry E. Storer, Michael Boeckh, Paul J. Martin, Jeannine S. McCune, David Myerson, Shelly Heimfeld, Mary E. Flowers, Claudio Anasetti, Kristine C. Doney, John A. Hansen, Hans-Peter Kiem, Richard A. Nash, Paul V. O’Donnell, Jerald P. Radich, Brenda M. Sandmaier, Bart L. Scott, Mohamed L. Sorror, E. Houston Warren, Robert P. Witherspoon, Ann Woolfrey, Frederick R. Appelbaum, Rainer Storb 
Biology of Blood and Marrow Transplantation 
Volume 12, Issue 5, Pages (May 2006)
DOI: /j.bbmt
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Cumulative incidence of GVHD: acute (A) and chronic (B). Shown separately are the incidences for patients given the prescribed doses of 4.5 or 6.0 mg/kg THY and patients who did not receive the prescribed dose (THY <4.5 mg/kg). The overall incidence of acute GVHD (grades II-IV) was 50%, and the overall incidence of extensive chronic GVHD was 34%.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Reactivation of CMV. Shown is the cumulative incidence of CMV antigenemia in patients conditioned with tBUCY + THY and tBUCY (concurrent controls). Low risk: donor and patient were seronegative; high risk: donor, patient, or both were seropositive.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Chronic GVHD in tBUCY + THY–conditioned patients and in concurrent and historical controls (conditioned with tBUCY). Shown are the cumulative incidences in tBUCY + THY–treated patients who received the prescribed doses of THY (PBPC, THY, 4.5 and 6.0) and tBUCY-conditioned concurrent (PBPC, concurrent) and historical controls (Bone Marrow, historical controls).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Outcome in patients conditioned with tBUCY + THY (this study) and in historical controls conditioned with tBUCY without THY. A, Cumulative incidence of relapse. B, Relapse-free survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions